[{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1.HTI","moa":"HIV T-cell immunogen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aelix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Aelix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vesatolimod","moa":"Toll-like receptor 7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aelix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aelix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"ChAdOx1.HTI","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aelix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Aelix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Aelix Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aelix Therapeutics \/ Aelix Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Aelix Therapeutics \/ Aelix Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Aelix Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The acquisition of the investigational assets for the HTI therapeutic vaccine, MVA.HTI, by Gilead Sciences marks a milestone in HIV research.

                          Product Name : MVA.HTI

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          November 25, 2024

                          Lead Product(s) : MVA.HTI,ChAdOx1.HTI,Vesatolimod

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : HTI-based vaccines as a component of combination cure regimens are being evaluated in the ongoing AELIX-003 clinical trial testing HTI in combination with Gilead’s investigational TLR7 agonist vesatolimod, in people living with HIV on ART.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 10, 2021

                          Lead Product(s) : Vesatolimod

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 13, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : Fundación FLS

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : ChAdOx1.HTI is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 27, 2020

                          Lead Product(s) : ChAdOx1.HTI

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Gilead Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : DNA.HTI is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          July 02, 2017

                          Lead Product(s) : DNA.HTI

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank